26 jul: Roche Gets FDA Clearance For Vitamin D Laboratory Test
26 jul: PKN Orlen Swings to Net Loss of PLN5.2 Million
26-07-2012 07:54:00

Sanofi Second-Quarter Net Profit up 16% Boosted by Tax Effect

Relateret indhold
Relateret debat
18 jan - 
UK Assignment Writing Help Service Say: Current capabil..
18 jan - 
Sanofi Outlines Next Wave of Innovative Medicines and V..
02 jan - 
Super godt indlæg! Tak for det. :)

By Noemie Bisserbe

PARIS--France's top drug maker Sanofi SA (SNY, SAN.FR) said Thursday it expected its earnings to fall this year, dented by the loss of patents on some of its blockbuster drugs, even as it posted a firm increase in second-quarter net profit, boosted by a tax effect.

The Paris-based pharmaceutical major said net profit attributable to shareholders rose 16% to 1.17 billion euros (US$1.4 billion) in the quarter ended June 30, from EUR1.01 billion a year earlier.

Business net income--the term it uses for adjusted income excluding items such as impacts associated with acquisitions and divestments--was, however, down 9.6% to EUR1.94 billion, hit by the loss of its patents on top-selling drugs--blood thinner Plavix and Avapro, a drug used to treat high blood pressure.

Analysts had forecast a second-quarter business net profit of EUR1.88 billion.

Sanofi's woes underscore drug makers' growing difficulty in keeping their heads above water as they swim from one blockbuster drug to another. On Wednesday, GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY) reported sharp drops in second-quarter net profit, hit by a wave of patent expirations for top-selling drugs.

Sanofi maintained its full-year guidance for a 12% to 15% decline in business earnings per share in 2012, assuming no major changes in exchange rates.

Analysts, however, expect Sanofi's earnings to rebound from 2013, as the group strives to rely less on innovative drug sales.

Sanofi, which is struggling with patent expirations, has been extending its pharmaceutical business to growth areas such as emerging markets, vaccines, diabetes solutions, consumer health care, innovative products and animal health, in a bid to become less dependent on patented medicines.

Net sales rose 6.2% to EUR8.87 billion, with revenue at the flagship pharmaceutical division increasing 5.1% to EUR7.5 billion.

Write to Noemie Bisserbe at noemie.bisserbe@dowjones.com

Order free Annual Report for Sanofi

Visit http://djnweurope.ar.wilink.com/?ticker=US80105N1054 or call +44 (0)208 391 6028

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 01:54 ET (05:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Roblon Q1: Bundlinjen næsten fordoblet

26-02-2015 16:36:53
Roblon kan notere sig en lille fremgang på toplinjen og et næsten fordoblet overskud i første kvartal af det forskudte regnskabsår sammenlignet med same periode..

Fakta: Kapløbet om det amerikanske marked for basal insulin

26-02-2015 13:49:38
Der er store milliardindtægter på spil for Novo Nordisk og selskabets konkurrenter på det amerikanske marked for langtidsvirkende insulin. Derfor kæmper selskab..

Aktier/åbning: Rekordkursen fortsætter - nu med William i front

26-02-2015 09:15:06
Rekordernes tid er tilsyneladende endnu ikke overstået. Det danske aktiemarked holder rekordkursen fra åbningen torsdag, efter at C20 Cap-indekset onsdag satte ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas: Goldwind slår analytikernes forventninger i årsregnskab
2
Aktier/tendens: Novo, WDH og Mærsk kan diktere retningen
3
Vestas-konkurrent fordobler overskud og opjusterer - NY
4
Novo: Ærkerival får grønt lys til nyt insulin - NY
5
Nationalbanken fastslår: Vi har rigeligt penge i kassen

Relaterede aktiekurser

Sanofi 87,45 -1,9% Fald i aktiekurs
Sanofi 48,87 -3,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Køb

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. februar 2015 23:57:51
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB3 - 2015-02-26 23:57:51 - 2015-02-26 23:57:51 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x